ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
MicroRNA-100-5p Exacerbates Myocardial Ischemia-Reperfusion Injury Through Downregulation of PRMT5.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute myocardial infarction (AMI) rates are rising due to the increasing prevalence of cardiac metabolic disorders, particularly diabetes mellitus (DM). While revascularization procedures such as coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) restore blood flow, they can also exacerbate myocardial ischemia-reperfusion (I/R) injury, for which current cardioprotective strategies remain insufficient. MicroRNAs are critical regulators of gene expression, but the role of miR-100-5p in I/R injury remains unclear. This study demonstrates that miR-100-5p is significantly upregulated in myocardial tissue during I/R injury, leading to the downregulation of protein arginine methyltransferase 5 (PRMT5). This reduction in PRMT5 impairs its capacity to methylate and inactivate Phosphatase and tensin homolog (PTEN), resulting in disruption of the PI3K-AKT signaling pathway, increased cardiomyocyte apoptosis, and aggravated myocardial damage. Using antisense oligomers to inhibit miR-100-5p, we restored PRMT5 expression, reactivated PI3K-AKT signaling, and reduced cardiomyocyte death, thereby mitigating myocardial injury. Our findings identify the miR-100-5p/PRMT5/PI3K-AKT axis as a key regulatory pathway in myocardial I/R injury and highlight miR-100-5p as a potential therapeutic target to protect the heart during revascularization procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.